The EMPA-KIDNEYCollaborative GroupHerringtonWGStaplinN, et al.Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med2023; 388(2): 117–127. DOI: 10.1056/NEJMoa2204233.
2.
PerkovicVJardineMJNealB, et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med2019; 380: 2295–2306.
3.
HeerspinkHJLStefanssonBVCorrea-RotterR, et al.Dapagliflozin in patients with chronic kidney disease. N Engl J Med2020; 383: 1436–1446.
4.
RossingPInzucchiSEVartP, et al.Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol2022; 10: 24–34.
5.
ZinmanBWannerCLachinJM, et al.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med2015; 373: 2117–2128.
6.
BalzerMSRongSNordlohneJ, et al.SGLT2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose dialysate. Biomolecules2020; 10(11): 1573.
7.
ShentuYLiYXieS, et al.Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-beta/Smad signaling. Int Immunopharmacol2021; 93: 107374.
8.
BargmanJMThorpeKEChurchillDN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol2001; 12: 2158–2162.
9.
TermorshuizenFKorevaarJCDekkerFW, et al.The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis2003; 41: 1293–1302.
10.
LeeMJParkJTParkKS, et al.Prognostic value of residual urine volume, GFR by 24-hour urine collection, and eGFR in patients receiving dialysis. Clin J Am Soc Nephrol2017; 12: 426–434.
11.
MartusGBerglingKde ArteagaJ, et al.SGLT2 inhibition does not reduce glucose absorption during experimental peritoneal dialysis. Perit Dial Int2021; 41: 373–380.
12.
MartusGBerglingKObergCM. Dual SGLT1/SGLT2 inhibitor phlorizin reduces glucose transport in experimental peritoneal dialysis. Perit Dial Int2023; 43(2); 145–150.
13.
BerglingKMartusGObergCM. Phloretin improves ultrafiltration and reduces glucose absorption during peritoneal dialysis in rats. J Am Soc Nephrol2022; 33: 1857–1863.
14.
BorkumMJamalASuneet SinghR, et al.The rationale for the need to study sodium-glucose co-transport 2 inhibitor usage in peritoneal dialysis patients. Perit Dial Int. Epub ahead of print 2 May 2022. DOI: 10.1177/08968608221096556.
15.
SchroppelBFischerederMWieseP, et al.Expression of glucose transporters in human peritoneal mesothelial cells. Kidney Int1998; 53: 1278–1287.
16.
SchrickerSOberackerTFritzP, et al.Peritoneal expression of SGLT-2, GLUT1, and GLUT3 in peritoneal dialysis patients. Kidney Blood Press Res2022; 47: 125–134.
17.
LiuHSridharVSBouletJ, et al.Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism2021; 126: 154918.
